PRIVILEGED AND CONFIDENTIAL Attorney-Client Privilege / Attorney Work Product
Updated Functional Analysis
Penterra Biopharma International DAC
(2017–2020)
Revised Version — March 15, 2023
Prepared by:
Calderwood & Harkness LLP 1735 Market Street, Suite 3100 Philadelphia, PA 19103
In coordination with:
Whitmore Valuation Group LLC 200 Ashbury Asset Advisors, Suite 700 Boston, MA 02109
Prepared for: Penterra Pharmaceuticals Corp. 2200 Independence Boulevard Princeton Junction, NJ 08550
Matter Number: 1018-00009
Classification: PRIVILEGED AND CONFIDENTIAL — Attorney-Client Privilege / Attorney Work Product. Prepared under the direction of counsel pursuant to Kovel arrangement (Ref: 1018-00009-KV). This memorandum and all information contained herein are protected by the attorney-client privilege and the work product doctrine. This document was prepared in anticipation of litigation and at the direction of counsel. No waiver of any privilege is intended or should be inferred from any disclosure of this document.
Authors:
• Garrett Simmons, Lead Associate, Calderwood & Harkness LLP
• Leila Nazari, Working Associate, Calderwood & Harkness LLP
• Dr. Helena Vasquez, Managing Director, Whitmore Valuation Group LLC
• Dr. Rohan Chakrabarti, Senior Director, Whitmore Valuation Group LLC
Supervising Attorneys:
• Leonard Cross, Responsible Partner, Calderwood & Harkness LLP
• Sylvia Hartwell, Billing Partner, Calderwood & Harkness LLP
Original Report Date: October 2022
Revised Report Date: March 15, 2023
Note on Revision: This revised functional analysis incorporates additional evidence gathered through the IRS Information Document Request ("IDR") process (47 IDRs issued between June 2022 and September 2023, of which approximately 30 had been responded to as of this revision date), supplemental PBI employee interviews conducted in Dublin during Q4 2022 and Q1 2023, and additional documentary evidence obtained from PBI, Penterra Manufacturing Ireland Ltd. ("PMI"), Thornbury & Keogh (Irish tax advisors), and Crestfield & Associates LLP (PPC's independent auditor and original transfer pricing documentation preparer). All substantive changes from the October 2022 original version are identified and discussed in Section XI of this memorandum. This revision supersedes the October 2022 version in its entirety.
Right-click to update Table of Contents
I. Executive Summary
This memorandum presents a comprehensive functional analysis of Penterra Biopharma International DAC ("PBI"), the Irish intellectual property holding and commercialization subsidiary of Penterra Pharmaceuticals Corp. ("PPC"), for tax years 2017, 2018, 2019, and 2020 (collectively, the "Examination Years"). These are the years currently under examination by the Internal Revenue Service ("IRS"), Large Business & International Division, Northeast Transfer Pricing Practice Area, Exam Team LB&I-NE-TP-2022-00641.
The IRS Large Business & International Division opened the current examination on May 16, 2022. The examination centers on and challenges the transfer pricing methodology used in PPC's Irish IP-holding structure, with particular focus on two intercompany arrangements: (1) the cost-sharing arrangement ("CSA") between PPC and PBI, under which PBI co-funds research and development costs in exchange for the right to exploit resulting pharmaceutical intellectual property outside the Americas; and (2) the legacy IP royalty arrangement between PPC and PBI, under which PBI pays a 4.5% royalty to PPC for the right to commercialize certain pre-2012 compounds in non-Americas territories.
The IRS has proposed adjustments totaling approximately $380.4 million across the four Examination Years (before correlative offsets and penalty computations). In particular, the IRS has proposed increases to PBI's cost-sharing percentages of approximately 8 to 12 percentage points above the ratios reflected on PPC's filed returns, resulting in proposed additional cost-sharing payments of approximately $235.01 million. The IRS has also proposed an increase to the legacy IP royalty rate from 4.5% to 11.0%, generating proposed additional royalty payments of approximately $188.04 million, with a correlative offset of approximately -$42.65 million. In addition, the IRS has proposed a penalty under IRC § 6662(e) of approximately $15.98 million.
Underlying these proposed adjustments, in whole or in part, is the IRS's assertion that PBI lacks sufficient economic substance to justify its role as an IP owner and CSA participant. The IRS has argued that the key functions relating to the Development, Enhancement, Maintenance, Protection, and Exploitation ("DEMPE") of PPC's pharmaceutical intellectual property remained in the United States, and that PBI was little more than a conduit or passive holding entity that did not perform the functions, bear the risks, or employ the assets that would warrant its entitlement to residual profits from non-Americas commercialization.
This functional analysis directly rebuts that position. Based on an exhaustive review of documentary evidence, a program of 24 in-person employee interviews conducted in Dublin, analysis of 42 board meetings held in Dublin during the Examination Years, review of regulatory submission records and expenditures totaling €47.2 million, examination of third-party distribution agreements covering 68 country markets, and analysis of banking records, capital expenditure documentation, and intercompany pricing decisions, we conclude as follows:
PBI is a substantive operating entity performing critical functions, bearing meaningful economic risks, and employing significant assets in its role as IP co-developer (under the CSA) and exclusive commercialization principal for non-Americas territories. PBI possesses genuine economic substance and performs DEMPE functions warranting its participation in the CSA and its entitlement to residual profits from non-Americas commercialization. PBI's functional profile is consistent with the arm's-length standard under IRC § 482 and Treasury Regulations §§ 1.482-4 and 1.482-7, as well as the OECD Transfer Pricing Guidelines' DEMPE framework.
This revised version of the functional analysis incorporates the following updates and enhancements from the original October 2022 version:
• 12 additional PBI employee interviews, bringing the total to 24 across both versions, including expanded coverage to mid-level personnel in regulatory, commercial, and finance functions;
• Expanded documentary evidence from board minutes analysis, encompassing all 42 meetings documented during the Examination Years with detailed analysis of governance decisions;
• Additional regulatory submission records with granular documentation of €47.2 million in cumulative expenditures across 68 country markets;
• Third-party distribution agreements produced under IDR Nos. 18 and 35, demonstrating PBI's independent commercial negotiations and autonomous pricing authority;
• Glenmore Bank Ireland plc banking records produced under IDR No. 22, confirming PBI's independent treasury operations, cash management capabilities, and financial capacity;
• Capital expenditure documentation produced under IDR No. 44 (preliminary data reviewed);
• Product-specific DEMPE analysis for Veritaxol, Imvara, and Cerulon; and
• Strengthened risk analysis with detailed documentation of risk control mechanisms.
This functional analysis should be read in conjunction with the economic analyses prepared by Whitmore Valuation Group LLC, including the CUT analysis (14 comparable uncontrolled license agreements, interquartile range 3.1%–6.8%, median 4.4%), the CPM/TNMM analysis (22 comparable companies), and the PCT DCF valuation (arm's-length range $278 million–$361 million at 9.8% WACC), as well as the separate DEMPE Functions Matrix workbook.
II. Scope and Methodology
II.A. Scope of Analysis
This functional analysis covers the four tax years currently under examination: TY 2017, TY 2018, TY 2019, and TY 2020. The analysis focuses primarily on the functional profile of Penterra Biopharma International DAC ("PBI"), the entity whose economic substance and DEMPE contributions are at the center of the IRS's challenge. However, where relevant for comparative purposes and to place PBI's functions in the context of the broader corporate group, this analysis also references the following affiliated entities:
• Penterra Pharmaceuticals Corp. ("PPC") — the U.S. parent corporation, organized as a Delaware corporation with headquarters at 2200 Independence Boulevard, Princeton Junction, NJ 08550. PPC is publicly traded on the Nasdaq Stock Market under the ticker symbol "PPCA." For fiscal year 2020, PPC reported consolidated global net revenue of approximately $6.82 billion, pre-tax income of approximately $1.47 billion, and employed approximately 14,500 employees worldwide. PPC is the U.S.-side participant in the CSA and performs laboratory-based research and development, Americas-territory commercialization, and global corporate functions.
• Penterra Holdings Luxembourg S.à r.l. ("PHL") — an intermediate holding entity organized under Luxembourg law, with its registered office at 14, rue Aldringen, L-1118 Luxembourg. PHL is 100% owned by PPC and serves as the direct parent of PBI. PHL is treated as a disregarded entity for U.S. federal income tax purposes and therefore does not appear as a separate taxpayer on PPC's consolidated federal income tax return. PHL's inclusion in this analysis is limited to its role in the corporate ownership chain.
• Penterra Manufacturing Ireland Ltd. ("PMI") — an Irish contract manufacturing entity, with its registered office at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland. PMI operates as a limited-risk contract manufacturer of PPC's oncology and immunology biologics for non-Americas markets, under a cost-plus arrangement (cost + 8% markup) with PBI. PMI employs approximately 620 manufacturing personnel. PMI's functional profile is that of a contract manufacturer, and it is compensated on a routine, cost-plus basis.
The corporate ownership structure is as follows:
PPC (Delaware corp., EIN: 22-3741856, HQ: Princeton Junction, NJ) → 100% owns PHL (Luxembourg S.à r.l., RCS No. B 168452; disregarded for U.S. tax) → 100% owns PBI (Irish DAC, Tax Ref: 3218764T, Sandyford Business Park, Dublin) PBI contracts with PMI (Irish Ltd., CRO No. 512347, Ringaskiddy, Co. Cork)
PBI is a Designated Activity Company organized and existing under the laws of Ireland, with its registered office at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI's Irish Tax Reference number is 3218764T. For fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI serves as the exclusive commercialization principal for PPC's pharmaceutical product portfolio outside the Americas and is a co-participant in the CSA, bearing a proportional share of the PPC Group's research and development costs in exchange for rights to exploit resulting intellectual property in non-Americas territories.
II.B. Regulatory and Legal Framework
This functional analysis is prepared against the backdrop of the following legal and regulatory authorities, which govern the transfer pricing treatment of the intercompany transactions at issue:
United States Authorities:
• IRC § 482 — The Commissioner's authority to allocate income, deductions, credits, or allowances among organizations, trades, or businesses that are owned or controlled directly or indirectly by the same interests, in order to prevent evasion of taxes or clearly to reflect income. The standard against which allocations under IRC § 482 are measured is the arm's-length standard.
• Treas. Reg. § 1.482-1(d) — The arm's-length standard and the best method rule. The best method rule requires selection of the transfer pricing method that provides the most reliable measure of an arm's-length result, considering the degree of comparability between the controlled transaction and any uncontrolled comparables, and the quality of the data and assumptions used in the analysis.
• Treas. Reg. § 1.482-4 — Methods applicable to transfers of intangible property, including the comparable uncontrolled transaction ("CUT") method, the comparable profits method ("CPM"), and other specified and unspecified methods. These regulations govern the arm's-length pricing of PBI's legacy IP royalty arrangement.
• Treas. Reg. § 1.482-7 — Qualification requirements and pricing rules for qualified cost-sharing arrangements ("QCSAs"). A QCSA must involve two or more controlled participants that share the costs and risks of developing intangibles in proportion to their reasonably anticipated benefits ("RAB") from exploitation of those intangibles. These regulations govern the arm's-length pricing of PBI's cost-sharing payments under the CSA.
• IRC § 367(d) — Rules applicable to outbound transfers of intangible property to foreign corporations, relevant to the initial platform contribution transaction ("PCT") by which PBI acquired rights to pre-existing IP from PPC.
• IRC § 6662(e) — The substantial valuation misstatement penalty applicable to transfer pricing adjustments, relevant to the IRS's proposed penalty of approximately $15.98 million. Penalty protection is available under IRC § 6662(e)(3) where the taxpayer maintains contemporaneous documentation meeting the requirements of Treas. Reg. § 1.6662-6.
OECD Authorities:
• OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (2017 and 2022 revisions) — While not binding on the United States, the OECD Guidelines are widely recognized as persuasive authority and reflect the international consensus on arm's-length transfer pricing principles. This functional analysis draws particularly on:
• Chapter VI — Special Considerations for Intangibles, including the DEMPE framework (Development, Enhancement, Maintenance, Protection, Exploitation), which provides a structured approach for identifying the functions performed, risks assumed, and assets used in connection with intangible property.
• Chapter VIII — Cost Contribution Arrangements, which addresses the arm's-length principles applicable to arrangements under which two or more associated enterprises share the costs and risks of developing, producing, or obtaining assets, services, or rights.
The DEMPE framework, introduced in the 2015 BEPS Action 8-10 Final Reports and incorporated into the 2017 OECD Guidelines, is directly relevant to the IRS's challenge, which asserts that PBI does not perform the DEMPE functions that would warrant its participation in the CSA and its entitlement to non-Americas residual profits.
II.C. Methodology and Sources
The analysis presented in this memorandum is based on a comprehensive review of documentary evidence, structured interviews with PBI personnel, and analysis of the intercompany transactions and arrangements between PBI and other entities within the PPC Group.
Employee Interviews
A total of 24 in-person interviews were conducted with PBI personnel at PBI's offices in Sandyford Business Park, Dublin, Ireland:
• Original interviews (August–September 2022): Twelve key PBI employees were interviewed in Dublin by Garrett Simmons (Lead Associate) and Leila Nazari (Working Associate) of Calderwood & Harkness LLP. These interviews were conducted as part of the original functional analysis prepared in October 2022. The interview subjects were selected to cover senior management, regulatory affairs, medical affairs, commercial strategy, supply chain, and finance functions, and were identified in consultation with PBI Managing Director Aidan Naughton.
• Supplemental interviews (November 2022–February 2023): Twelve additional PBI employees were interviewed in Dublin by the same interview team, expanding coverage to mid-level personnel in regulatory, commercial, and finance functions. The supplemental interview subjects were identified based on the IRS's specific focus on DEMPE functions and the need to demonstrate that independent decision-making occurs not only at the senior management level but throughout PBI's organization.
Each interview followed a structured protocol designed to document the interviewee's role and responsibilities, decision-making authority, functional contributions to non-Americas commercialization, reporting lines (both internal to PBI and any coordination with PPC), and day-to-day activities performed in Dublin. Detailed interview summaries are maintained in a separate memorandum entitled "PBI Personnel Interview Summaries — 24 Interviews (August 2022 – February 2023)" and are cross-referenced in Appendix D.
Documentary Sources Reviewed
The following documentary sources were reviewed in the preparation of this functional analysis:
• PBI board minutes for 42 meetings held in Dublin during the Examination Years (2017–2020), comprising quarterly meetings and special sessions. Board minutes were analyzed for evidence of substantive governance activity, including approval of budgets, market entry decisions, pricing strategy approvals, regulatory submission decisions, and distribution partner selection. A detailed analysis of these board minutes is presented in a separate companion memorandum entitled "Analysis of PBI Board Minutes — 42 Meetings (2017–2020)."
• PBI organizational charts and employee records, produced in response to IDR No. 8, documenting the growth and composition of PBI's workforce from inception through the end of the Examination Years.
• The CSA agreement effective July 1, 2012, together with all amendments thereto, produced in response to IDR No. 2. This agreement establishes the terms under which PBI co-funds PPC's research and development costs and acquires rights to exploit resulting IP outside the Americas.
• The legacy IP license agreement, providing for a 4.5% royalty rate on non-Americas net sales of pre-2012 compounds, produced in response to IDR No. 3.
• The PMI contract manufacturing agreement, under which PMI manufactures biologics for non-Americas markets on a cost + 8% markup basis, produced in response to IDR No. 10.
• PBI financial statements and Irish tax returns for TY 2017–2020, produced in response to IDR No. 7, providing the financial data underlying the economic analysis of PBI's operations and profitability.
• Third-party distribution agreements for non-Americas territories, produced in response to IDR No. 18 (response received December 5, 2022). These agreements document PBI's independent negotiation and management of distribution relationships across 68 country markets.
• PBI regulatory expenditure and submission records, produced in response to IDR No. 15 (response received November 8, 2022). These records document cumulative regulatory expenditures of €47.2 million during the Examination Years (2017–2020) and provide detailed information on PBI's regulatory submissions to non-U.S. regulatory authorities.
• PBI office lease for approximately 18,000 square feet at Sandyford Business Park, Dublin D18 K7T4, produced in response to IDR No. 12 (response received October 12, 2022). This lease documents PBI's physical presence in Ireland.
• PBI banking records with Glenmore Bank Ireland plc, produced in response to IDR No. 22 (response received January 20, 2023). These records document PBI's independent treasury operations, cash management, payment flows, and financial capacity.
• PBI capital expenditure and investment records, subject to IDR No. 44. As of this revision date, the full response to IDR No. 44 is anticipated; however, preliminary data has been made available and has been reviewed.
• Intercompany pricing decisions and market strategy documents, subject to IDR No. 35 (full response anticipated June 2, 2023). Preliminary evidence has been reviewed, confirming PBI's autonomous pricing authority across 68 non-Americas markets.
• Forms 5471 filed for PBI and PHL for TY 2017–2020, subject to IDR No. 40 (full response anticipated).
• Original transfer pricing documentation prepared by Crestfield & Associates LLP (Susan Lam, Transfer Pricing Partner, 1200 Avenue of the Americas, New York, NY 10036) for TY 2017–2020, produced in response to IDR No. 4. This documentation was prepared under the contemporaneous documentation requirements of IRC § 6662(e) and Treas. Reg. § 1.6662-6.
• Irish tax filings and Knowledge Development box ("KDB") claims, coordinated with Ciarán Thornbury, Lead Partner, Thornbury & Keogh, 22 Fitzwilliam Square, Dublin 2, D02 YH68, Ireland, and produced in response to IDR No. 30.
• Comparable license agreements identified and analyzed by Whitmore Valuation Group LLC in support of the CUT analysis (IDR No. 25 response, received February 15, 2023), providing further corroboration of the arm's-length royalty rate for the legacy IP license arrangement.
• Additional data obtained from Crestfield & Associates (coordinated through Garrett Simmons) on R&D cost pool composition, qualified cost-sharing ratios, and transfer pricing workpapers.
III. Background on PBI and the PPC Group IP Structure
III.A. Incorporation and Establishment of PBI
Penterra Biopharma International DAC ("PBI") was incorporated on March 15, 2012, as a Designated Activity Company under Irish law. The decision to establish PBI in Ireland reflected a strategic determination by PPC's senior management and board of directors to create a substantive operating platform for the commercialization of PPC's pharmaceutical product portfolio outside the Americas. Ireland was selected as the location for PBI in light of several factors, including Ireland's established pharmaceutical and biopharmaceutical industry ecosystem, the availability of experienced regulatory, medical affairs, and commercial talent, Ireland's membership in the European Union and its access to the EU single market, and Ireland's competitive corporate tax environment, including the standard trading rate of 12.5% and the Knowledge Development box regime.
PBI's registered office is located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI's Irish Tax Reference number is 3218764T.
PBI is 100% owned by Penterra Holdings Luxembourg S.à r.l. ("PHL"), a Luxembourg société à responsabilité limitée with Luxembourg Registre de Commerce et des Sociétés ("RCS") Number B 168452, which in turn is 100% owned by Penterra Pharmaceuticals Corp. ("PPC"), a Delaware corporation with Employer Identification Number ("EIN") 22-3741856. PHL was established as an intermediate holding entity within the PPC Group corporate structure; for U.S. federal income tax purposes, PHL is treated as a disregarded entity, meaning that PBI is treated as a direct subsidiary of PPC for purposes of PPC's consolidated federal income tax return.
Aidan Naughton was appointed as Managing Director of PBI at inception and has served continuously in that role through the Examination Years and to the present date. Mr. Naughton is an Irish national, resident in Ireland, and based full-time at PBI's offices in Sandyford Business Park. He bears overall responsibility for PBI's operations, commercial strategy, and profit-and-loss performance. Mr. Naughton reports to the PPC board of directors on matters of global corporate governance but exercises independent judgment on decisions relating to non-Americas commercialization, regulatory strategy, pricing, market entry, and distribution partner selection.
III.B. Cost-Sharing Arrangement
The CSA between PPC and PBI was executed effective July 1, 2012. The CSA was structured to comply with the requirements of Treas. Reg. § 1.482-7 for qualified cost-sharing arrangements. Under the CSA, PBI acquired the right to co-develop and exploit PPC's pharmaceutical intellectual property portfolio outside the Americas, defined in the CSA as North America, Central America, South America, and the Caribbean (collectively, the "Americas"). PPC retained exclusive rights to exploit the same IP within the Americas.
Platform Contribution Transaction ("PCT"): As consideration for PBI's buy-in to PPC's pre-existing intellectual property portfolio — which at the time of the CSA's execution included primarily clinical-stage and approved oncology compounds, as well as a pipeline of immunology and rare disease candidates — PBI made a lump-sum PCT payment of $312 million to PPC on July 1, 2012. This PCT payment was determined through a discounted cash flow analysis performed by Crestfield & Associates LLP at the time of the CSA's execution. The arm's-length nature of the PCT payment, including the underlying valuation methodology, is addressed in the separate economic analysis prepared by Whitmore Valuation Group LLC (PCT DCF valuation — arm's-length range $278 million–$361 million at a 9.8% weighted average cost of capital ("WACC")).
Ongoing Cost-Sharing: Under the CSA, PBI co-funds PPC's qualified research and development costs on an annual basis, with PBI's share determined proportionally based on reasonably anticipated benefits ("RAB") from exploitation of the resulting intangibles. The RAB ratios are computed annually based on projected revenue streams from each participant's assigned territory. PBI's cost-sharing ratios and payments during the Examination Years were as follows:
The gradual increase in PBI's cost-sharing percentage over the Examination Years reflects the growing proportion of non-Americas revenue in the PPC Group's total revenue, consistent with PBI's expanding commercial operations and successful market penetration in EMEA and APAC territories. This upward trajectory is itself evidence of PBI's substantive contribution to commercialization: as PBI's non-Americas operations grew in scope and success, the RAB methodology correctly attributed a larger share of anticipated benefits — and therefore a larger share of R&D funding obligations — to PBI.
III.C. Legacy IP Royalty Arrangement
Separate from the CSA, PBI licenses certain legacy compounds from PPC under a separate intercompany license agreement. These legacy compounds are pre-2012 vintage compounds that were already approved and commercially available at the time the CSA was executed on July 1, 2012. Because these compounds were not included in the CSA's scope (which covers only post-July 1, 2012 development activity), PBI's right to commercialize these legacy products in non-Americas territories is governed by a standalone royalty license.
The royalty rate under this license is 4.5% of net sales of legacy compounds in non-Americas territories. This rate was established based on a CUT analysis performed by Crestfield & Associates LLP at the time the license was executed, using comparable uncontrolled pharmaceutical license agreements. The arm's-length nature of the 4.5% royalty rate has been further corroborated by the updated CUT analysis performed by Whitmore Valuation Group LLC, which identified 14 comparable uncontrolled license agreements and determined an interquartile range of 3.1% to 6.8%, with a median of 4.4%. PPC's 4.5% royalty rate falls within this interquartile range and is closely aligned with the median.
Legacy compound non-Americas net sales and corresponding royalty payments during the Examination Years were as follows:
The declining trajectory of legacy compound sales reflects the natural product lifecycle of these older compounds, including patent expirations, generic competition, and therapeutic substitution. This declining revenue trend is consistent with arm's-length behavior: a royalty licensee operating at arm's length would expect diminishing returns from legacy products as they age, and PBI's results reflect precisely this pattern.
III.D. Contract Manufacturing — PMI
Penterra Manufacturing Ireland Ltd. ("PMI") is an Irish limited liability company, with Irish Companies Registration Office ("CRO") Number 512347, and its registered office at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland. PMI operates as a contract manufacturer of PPC's oncology and immunology biologics for non-Americas markets.
PMI operates under a contract manufacturing agreement with PBI pursuant to which PMI manufactures finished pharmaceutical products to PBI's specifications and delivers them to PBI or to third-party logistics providers designated by PBI. PMI is compensated on a cost-plus basis, receiving reimbursement of its fully loaded manufacturing costs plus an 8% markup. This cost-plus structure is consistent with PMI's functional profile as a limited-risk contract manufacturer: PMI does not bear entrepreneurial risk, does not own the underlying intellectual property, does not set pricing for finished products, and does not make commercialization decisions. PMI's approximately 620 employees are manufacturing personnel engaged in the production of biologics at the Ringaskiddy facility.
PBI, as the non-Americas principal, bears the entrepreneurial and residual risks associated with the commercialization of products manufactured by PMI. PBI directs the manufacturing relationship, determines production schedules and volumes, manages inventory levels, and bears the risk of unsold inventory. The PMI contract manufacturing arrangement has been tested under the CPM/TNMM methodology and produces results within the arm's-length interquartile range for comparable contract manufacturing arrangements.
III.E. Key Products
PBI's non-Americas commercialization activity during the Examination Years centered on three key products:
Veritaxol (Oncology): Veritaxol is PPC's blockbuster oncology compound and the single largest revenue contributor within the PPC Group. Veritaxol is indicated for the treatment of several types of solid tumors and has achieved widespread adoption across global markets. For fiscal year 2020, Veritaxol generated global net sales of approximately $3.12 billion. Non-Americas net sales (PBI's territory) accounted for approximately $1.34 billion, or approximately 43% of global Veritaxol revenue. The non-Americas share of Veritaxol revenue reflects PBI's successful market penetration and commercial execution across EMEA and APAC territories, including markets with complex reimbursement environments, diverse regulatory requirements, and varied competitive landscapes.
Imvara (Immunology): Imvara is an immunology compound indicated for the treatment of moderate-to-severe autoimmune conditions. For fiscal year 2020, Imvara generated global net sales of approximately $1.87 billion. Non-Americas net sales (PBI's territory) accounted for approximately $0.79 billion, or approximately 42% of global Imvara revenue. PBI's medical affairs team has played a significant role in supporting the commercial success of Imvara in non-Americas markets through KOL engagement, post-marketing study design and execution, and label extension strategies tailored to the regulatory requirements of individual non-Americas jurisdictions.
Cerulon (Rare Disease): Cerulon is a rare disease product indicated for the treatment of a specific metabolic disorder. For fiscal year 2020, Cerulon generated global net sales of approximately $0.62 billion. Non-Americas net sales (PBI's territory) accounted for approximately $0.28 billion, or approximately 45% of global Cerulon revenue. Cerulon's relatively higher non-Americas share reflects the strong demand for orphan drug therapies in European and Asian markets and PBI's success in navigating the complex pricing and reimbursement frameworks applicable to rare disease products in these territories.
IV. PBI Organizational Structure and Personnel
IV.A. Headcount Growth and Composition
PBI's workforce has grown steadily since the entity's establishment in 2012, reflecting the expansion of non-Americas commercialization activities and the development of PBI's operational capabilities. At inception in 2012, PBI employed 52 individuals. By the end of TY 2020, PBI's headcount had grown to 185 employees, representing a compound annual growth rate of approximately 17% over the period. This growth trajectory is itself probative of PBI's genuine economic substance: a "brass plate" entity or passive holding company would not need — and would not invest in — a workforce of this size and composition.
The composition of PBI's workforce as of December 31, 2020 (the end of the last Examination Year), broken down by functional department, was as follows:
Several features of this breakdown merit emphasis. First, the largest single department is Commercial Strategy and Marketing (45 employees), reflecting PBI's role as the active commercialization principal for non-Americas territories. These personnel are responsible for setting pricing strategies, managing distributor relationships, planning market entry, developing marketing campaigns, and executing commercial strategies across 68 country markets. Second, the Regulatory Affairs department (32 employees) represents a significant investment in regulatory capability, reflecting PBI's independent role in preparing and managing regulatory submissions to non-U.S. regulatory authorities. Third, the Medical Affairs department (28 employees) is responsible for KOL engagement, clinical support activities, and post-marketing studies, functions that are central to the Enhancement and Maintenance of IP value in non-Americas markets. Fourth, the Supply Chain and Operations department (30 employees) manages the PMI contract manufacturing relationship, coordinates logistics across multiple markets, and oversees inventory management.
The Finance, Legal, and Administration department (38 employees) includes treasury management, accounts payable and receivable, tax compliance support, legal support for distribution agreements and regulatory matters, human resources, and general administration. This department's size reflects PBI's status as an independent operating entity that manages its own financial affairs, maintains its own banking relationships, and handles its own compliance obligations.
IV.B. Key Personnel
The following key personnel were identified through the interview program and documentary analysis as performing critical functions within PBI during the Examination Years:
Managing Director — Aidan Naughton: Mr. Naughton has served as Managing Director of PBI since the entity's inception in March 2012. He bears overall responsibility for PBI's operations, commercial strategy, regulatory affairs, and profit-and-loss performance in non-Americas territories. Mr. Naughton reports to PPC's board of directors on matters of global corporate governance, but exercises independent judgment on all decisions relating to non-Americas commercialization, including pricing, market entry, distribution partner selection, regulatory submission strategy, and capital allocation. Mr. Naughton is an Irish national, resident in Ireland, and is based full-time at PBI's offices in Sandyford Business Park, Dublin. He was present at all 42 board meetings held in Dublin during the Examination Years (2017–2020) and chaired the majority of those meetings.
Director of Regulatory Affairs: This individual leads PBI's 32-person regulatory affairs department and is responsible for directing country-specific regulatory strategies across non-Americas territories, managing interactions with non-U.S. regulatory authorities (including the European Medicines Agency ("EMA"), the UK Medicines and Healthcare products Regulatory Agency ("MHRA"), the Australian Therapeutic Goods Administration ("TGA"), and numerous national regulatory agencies), overseeing regulatory submissions and label extension applications, and managing PBI's cumulative regulatory expenditures of €47.2 million during the Examination Years.
Director of Medical Affairs: This individual leads PBI's 28-person medical affairs department and is responsible for KOL engagement across EMEA and APAC territories, post-marketing study design and execution, clinical support activities, and identification of unmet medical needs in non-Americas markets that may inform development and enhancement strategies for PBI's product portfolio.
Vice President, Commercial Strategy: This individual leads PBI's 45-person commercial strategy and marketing department and is responsible for developing and executing commercial strategies across 68 country markets, including pricing decisions, marketing campaigns, competitive analysis, and market access strategies. This individual has autonomous authority to negotiate terms with third-party distribution partners and to make market entry and withdrawal decisions in coordination with Mr. Naughton.
Head of Supply Chain and Operations: This individual leads PBI's 30-person supply chain and operations team and is responsible for managing the PMI contract manufacturing relationship, coordinating production scheduling and quality oversight, managing inventory levels and third-party logistics, and ensuring continuity of supply across non-Americas markets.
Head of Finance: This individual leads PBI's finance function and is responsible for treasury management, budgeting and financial planning, accounts payable and receivable management, tax compliance support (in coordination with Thornbury & Keogh), management of PBI's banking relationship with Glenmore Bank Ireland plc, and foreign exchange risk management.
All key decision-makers within PBI are resident and working in Ireland. No key PBI personnel commute from or are based in the United States or any other jurisdiction outside of Ireland.
IV.C. Employee Interview Program
The employee interview program was designed to provide direct, first-hand evidence of the functions performed by PBI personnel, the nature and scope of their decision-making authority, and the extent to which PBI operates as a genuinely independent and substantive entity. The program consisted of two phases:
Phase 1 — Original Interviews (August–September 2022): Twelve key PBI employees were interviewed in person at PBI's offices in Sandyford Business Park, Dublin, by Garrett Simmons and Leila Nazari of Calderwood & Harkness LLP. The interview subjects were selected to provide coverage of PBI's senior management, regulatory affairs, medical affairs, commercial strategy, supply chain, and finance functions, and were identified in consultation with Managing Director Aidan Naughton and Calderwood & Harkness's supervising partners. Each interview lasted approximately 90 minutes to two hours and followed a structured protocol designed to elicit detailed information about the interviewee's role, responsibilities, decision-making authority, reporting lines, day-to-day activities, and functional contributions to non-Americas commercialization.
Phase 2 — Supplemental Interviews (November 2022–February 2023): Following the IRS's issuance of additional IDRs and the development of a more specific understanding of the IRS's economic substance challenge, twelve additional PBI employees were interviewed under the same protocol. The supplemental interview subjects were selected to expand coverage to mid-level personnel in regulatory, commercial, and finance functions, thereby demonstrating that independent decision-making occurs not only at the senior management level but throughout PBI's organizational structure.
Total Interview Subjects: 24 individuals across both phases.
The interviews yielded several consistent and important themes:
• Independent Pricing Authority: PBI personnel exercise independent judgment on pricing decisions across 68 country markets. Pricing strategies are developed by PBI's commercial strategy team in Dublin, taking into account local market conditions, competitive dynamics, government reimbursement frameworks, and local health technology assessment ("HTA") requirements. Pricing decisions are not dictated or pre-determined by PPC personnel in the United States.
• Independent Regulatory Decision-Making: Regulatory submission decisions are made in Dublin by PBI's regulatory affairs team, with local regulatory expertise guiding country-specific strategies. While PBI's regulatory team coordinates with PPC on global regulatory matters (such as the content of global dossiers), the decisions about when, where, and how to submit regulatory filings in non-Americas jurisdictions are made by PBI personnel in Dublin.
• Independent Commercial Negotiations: PBI's commercial team independently negotiates with third-party distributors across 68 country markets. Distribution agreements are drafted, negotiated, and executed by PBI personnel, and the selection of distribution partners is a PBI decision made in Dublin.
• Medical Affairs Activities Directed from Dublin: PBI's medical affairs activities, including KOL engagement, post-marketing study management, and clinical support, are directed from Dublin by PBI's medical affairs team. These activities contribute directly to the maintenance and enhancement of the value of PPC's pharmaceutical IP in non-Americas territories.
• Supply Chain Management: PBI personnel manage the PMI contract manufacturing relationship and third-party logistics from Dublin, including production scheduling, quality oversight, inventory management, and distribution logistics.
Detailed summaries of each interview, including the interviewee's name, department, role, interview date, interviewer, and key findings, are maintained in a separate memorandum entitled "PBI Personnel Interview Summaries — 24 Interviews (August 2022 – February 2023)" and are indexed in Appendix D.
IV.D. Physical Presence and Infrastructure
PBI occupies approximately 18,000 square feet of dedicated office space at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. The lease for this space has been documented and produced to the IRS under IDR No. 12 (response received October 12, 2022). The leased premises house all 185 PBI employees and contain:
• Dedicated conference rooms for board meetings and senior management discussions
• Open-plan and private office space for all functional departments (regulatory affairs, medical affairs, commercial strategy, supply chain, finance, legal, and administration)
• IT infrastructure, including servers, secure network connections, and telecommunications systems
• Secure document storage for regulatory filings, commercial contracts, and confidential business records
• Meeting rooms and collaboration spaces used for interactions with third-party distributors, consultants, and advisors
The physical evidence of PBI's operational presence is significant. PBI is not a "brass plate" entity, a shell corporation, or a passive holding company with a nominal registered address. PBI maintains a genuine, fully operational office staffed by 185 employees who perform their duties on a daily basis from Dublin. This physical presence is consistent with PBI's role as a substantive operating entity and is directly at odds with the IRS's characterization of PBI as lacking economic substance.
V. DEMPE Functions Analysis
V.A. Framework
The OECD Transfer Pricing Guidelines, Chapter VI (Special Considerations for Intangibles), introduced the DEMPE framework as a structured approach for analyzing the functions performed, risks assumed, and assets used in connection with intangible property. DEMPE stands for Development, Enhancement, Maintenance, Protection, and Exploitation — the five categories of functions that contribute to the creation, maintenance, and realization of value from intangible assets.
Under the OECD's framework, legal ownership of intangible property alone does not entitle an entity to the returns from that property. Instead, the OECD Guidelines provide that "the entity that is entitled to share in the returns derived by the MNE group from the exploitation of the intangible" must be determined by reference to the functions performed, risks assumed, and assets used by each entity in connection with the development, enhancement, maintenance, protection, and exploitation of the intangible. An entity that performs significant DEMPE functions, bears and controls the associated risks, and employs the necessary assets is entitled to a commensurate share of the returns from the intangible.
Under U.S. law, the analysis proceeds under IRC § 482 and Treas. Reg. § 1.482-7. A controlled participant in a QCSA must perform functions, bear risks, and employ assets consistent with its share of reasonably anticipated benefits from the exploitation of intangibles developed under the arrangement. The regulations require that each participant exercise control over the risks it bears and have the financial capacity to bear those risks.
The IRS's economic substance challenge asserts that key DEMPE functions remained in the United States, performed by PPC personnel, and that PBI's role was limited to passive ownership and receipt of residual income. This section demonstrates that PBI performs substantial DEMPE functions from its operations in Ireland, warranting its participation in the CSA and its entitlement to residual profits from non-Americas commercialization.
V.B. Development Functions
PBI performs meaningful Development functions in connection with PPC's pharmaceutical intellectual property portfolio for non-Americas territories.
Financial Contribution to R&D: PBI co-funds PPC's qualified research and development costs under the CSA. During the Examination Years, PBI's annual cost-sharing payments ranged from $186.15 million (2017) to $255.52 million (2020), for a cumulative total of approximately $879.74 million across the four Examination Years. These payments represent a substantial financial commitment to the development of new pharmaceutical IP, and they are funded from PBI's own revenue and cash resources, not from intercompany borrowings or upstream funding from PPC.
The IRS may argue that financial contribution alone does not constitute performance of Development functions. This analysis agrees that financial contribution is a necessary but not sufficient condition for entitlement to Development returns. However, PBI's Development contribution extends well beyond mere funding.
Regulatory Development Activities: PBI's regulatory affairs team in Dublin directs the development pathway for PPC's compounds in non-Americas markets. This includes:
• Country-specific regulatory strategies: PBI's regulatory affairs department develops and executes regulatory strategies tailored to the requirements of individual non-Americas jurisdictions. Each country market has its own regulatory authority, submission requirements, clinical data expectations, and approval timelines. PBI's team of 32 regulatory professionals manages these requirements independently, without reliance on PPC's U.S.-based regulatory function.
• Interactions with non-U.S. regulatory authorities: PBI personnel are the primary point of contact with non-U.S. regulatory authorities, including the EMA, MHRA, TGA, Health Canada (for non-Americas coordination purposes where applicable), Japan's Pharmaceuticals and Medical Devices Agency ("PMDA"), and numerous national regulatory agencies across EMEA and APAC. PBI manages pre-submission meetings, responds to regulatory queries, and oversees the approval process in each jurisdiction.
• Adaptation of clinical trial protocols: PBI's regulatory and medical affairs teams adapt clinical trial protocols developed by PPC's U.S.-based R&D organization for non-Americas markets, taking into account local regulatory requirements, patient population characteristics, standard-of-care differences, and ethical review requirements in non-U.S. jurisdictions.
Medical Affairs Contribution to Development: PBI's medical affairs team (28 employees) contributes to Development by identifying unmet medical needs in non-Americas territories that may inform the direction of PPC's R&D pipeline. Through its extensive KOL network in EMEA and APAC, PBI provides PPC's R&D organization with insights into local disease epidemiology, treatment patterns, and clinical practice that shape the design and prioritization of clinical development programs.
Control Over Development Activity: PBI exercises control over the Development activity to the extent it affects non-Americas markets, consistent with the CSA. PBI's Managing Director and senior regulatory team participate in joint R&D governance meetings with PPC and have the authority to direct non-Americas-specific development activities, including the sequencing and prioritization of regulatory submissions across non-Americas jurisdictions.
V.C. Enhancement Functions
PBI performs substantial Enhancement functions that increase the value of PPC's pharmaceutical IP in non-Americas territories.
Product Enhancement Opportunities: PBI personnel in Dublin identify and pursue product enhancement opportunities specifically for non-Americas markets, including:
• Formulation requirements: PBI's supply chain and regulatory teams identify formulation adaptations required for specific country markets, including cold-chain requirements for temperature-sensitive biologics in tropical climates, packaging and labeling requirements to meet local language and regulatory specifications, and dosage form modifications to address local clinical practice preferences.
• Label extensions and new indication strategies: PBI's medical affairs team leads the identification and development of label extension opportunities in non-Americas markets. In several instances during the Examination Years, PBI's medical affairs team identified new therapeutic indications for existing products that were pursued first in non-Americas jurisdictions based on regulatory pathway considerations, local unmet medical needs, and the strength of PBI's KOL relationships.
• Post-marketing studies: PBI initiates and manages post-marketing studies required or requested by non-Americas regulatory authorities as a condition of marketing authorization or as part of ongoing pharmacovigilance obligations. These studies generate data that enhances the product's regulatory and commercial value in the territories where they are conducted and, in many cases, contributes to the global evidence base supporting the product's safety and efficacy profile.
Regulatory Expenditures: PBI's cumulative regulatory expenditure on submissions across non-Americas territories during the Examination Years totaled €47.2 million. This figure is documented in detail in the records produced under IDR No. 15 (response received November 8, 2022). These expenditures represent direct investment by PBI in regulatory capital — i.e., the body of regulatory submissions, marketing authorizations, and regulatory data that creates and preserves the legal right to market PPC's products in non-Americas jurisdictions. This regulatory capital is itself an intangible asset owned by PBI and is an essential component of the value chain in non-Americas markets.
Value Creation: The Enhancement activities performed by PBI — including formulation adaptations, label extensions, and post-marketing studies — directly create and preserve value in the non-Americas IP. These activities are not performed by PPC in the United States. They are performed by PBI personnel in Dublin, using PBI's resources and capabilities, and they enhance the commercial potential of PPC's products in the territories assigned to PBI under the CSA.
V.D. Maintenance Functions
PBI performs critical Maintenance functions that preserve and sustain the commercial value of PPC's pharmaceutical IP in non-Americas territories.
Key Opinion Leader Relationships: PBI's medical affairs team maintains ongoing relationships with KOLs in EMEA and APAC. These relationships are essential to maintaining the scientific and clinical reputation of PPC's products in non-Americas markets. PBI's KOL engagement activities include advisory board meetings, speaker programs, investigator-initiated research support, and medical education initiatives. These activities are planned, budgeted, and executed by PBI personnel in Dublin.
Pharmacovigilance and Adverse Event Monitoring: PBI's regulatory affairs and medical affairs teams manage pharmacovigilance and adverse event monitoring obligations for non-Americas markets. These obligations require ongoing surveillance, reporting, and risk management activities that are critical to maintaining the marketing authorization and commercial viability of PPC's products in non-Americas jurisdictions.
Product Quality Oversight: PBI's supply chain team manages the PMI contract manufacturing relationship, including quality oversight, manufacturing audits, and compliance monitoring. PBI bears the responsibility for ensuring that products manufactured by PMI meet regulatory requirements and quality standards applicable in non-Americas markets. This quality oversight function is a Maintenance activity that preserves the value of the IP by protecting the reputation and regulatory status of PPC's products.
Lifecycle Management: PBI develops and implements lifecycle management strategies for Veritaxol, Imvara, and Cerulon in non-Americas markets. These strategies include managing patent cliffs, preparing for generic or biosimilar competition, optimizing pricing and reimbursement positioning, and developing succession plans for products approaching the end of their commercial lifecycle. PBI's lifecycle management activities are distinct from and independent of PPC's lifecycle management for the same products in the Americas.
Supply Chain Management: PBI's supply chain and operations team (30 employees) manages manufacturing scheduling with PMI, coordinates inventory levels across multiple non-Americas markets, oversees third-party logistics and distribution, and ensures continuity of supply. These supply chain functions are critical to maintaining the commercial value of PPC's products in non-Americas territories, as supply disruptions can lead to loss of market share, regulatory sanctions, and patient harm.
V.E. Protection Functions
PBI manages the protection of PPC's intellectual property in non-Americas territories, performing functions that safeguard the legal and commercial value of the IP.
Patent Management: PBI coordinates patent filings, enforcement, and defense in EMEA and APAC jurisdictions. This includes managing national-phase patent applications, opposing generic patent challenges, and enforcing patent rights against potential infringers. PBI engages and directs local patent counsel in key non-Americas markets to handle jurisdiction-specific patent matters.
IP Enforcement: PBI engages local counsel for intellectual property enforcement matters in key non-Americas markets, including trademark infringement actions, counterfeiting investigations, and regulatory data protection disputes. PBI manages these matters from Dublin, making strategic decisions about when and where to initiate enforcement proceedings.
Trademark and Brand Protection: PBI manages trademark registration, renewal, and protection for PPC's pharmaceutical brands in non-Americas territories. PBI's legal function coordinates with local trademark counsel to monitor and respond to potential infringement, manage oppositions, and maintain trademark portfolios across 68 country markets.
Data Exclusivity Management: PBI manages data exclusivity protections applicable to regulatory submissions made by PBI in non-Americas jurisdictions. Data exclusivity provides a period of market protection during which generic or biosimilar applicants cannot rely on PBI's regulatory data. PBI's regulatory affairs team monitors and enforces these data exclusivity rights as part of the broader IP protection strategy.
V.F. Exploitation Functions
PBI is the exclusive principal for the commercialization of PPC's pharmaceutical products outside the Americas. PBI's Exploitation functions are the most visible manifestation of its economic substance and operational independence.
Exclusive Commercialization Principal: PBI holds the exclusive right — under the CSA (for post-2012 IP) and the legacy license (for pre-2012 IP) — to exploit PPC's pharmaceutical products in non-Americas territories. PBI is not a mere distributor or commission agent; it is the entrepreneurial principal that bears the residual commercial risk of non-Americas sales and is entitled to the residual profit (or loss) from those sales.
Independent Pricing Decisions: PBI independently sets pricing across 68 country markets in EMEA and APAC. This pricing authority is documented in the intercompany pricing decisions and market strategy documents produced under IDR No. 35. PBI's commercial strategy team develops pricing strategies that reflect local market conditions, competitive dynamics, government reimbursement frameworks, HTA requirements, and patient access considerations. Pricing decisions are made in Dublin by PBI personnel and are not dictated or pre-approved by PPC headquarters in New Jersey.
Distribution Partner Management: PBI selects, negotiates with, and manages third-party distribution partners across its 68 country markets. The third-party distribution agreements produced under IDR No. 18 demonstrate that PBI is the contracting party, that PBI's commercial team negotiates the terms of these agreements, and that PBI manages the ongoing distributor relationships from Dublin. Distribution partner selection involves significant commercial judgment, including assessment of the distributor's market reach, capabilities, creditworthiness, and regulatory compliance record.
Market Entry Strategy: PBI determines the timing and strategy for market entry in new non-Americas markets. Market entry decisions involve assessment of regulatory feasibility, market size, competitive landscape, reimbursement environment, and distribution infrastructure. These decisions are made by PBI's senior management team in Dublin, with Aidan Naughton exercising final decision-making authority.
Commercial Risk Bearing: PBI bears the full range of commercial risks associated with non-Americas commercialization, including market risk, credit risk, inventory risk, pricing/reimbursement risk, and foreign exchange risk. These risks are not borne by PPC or by any other entity within the PPC Group. PBI's P&L directly reflects the commercial success or failure of non-Americas operations.
Revenue Generation: PBI's non-Americas revenue demonstrates the scale and substantive nature of its Exploitation activities:
These figures represent substantial commercial activity, not passive receipt of royalty or licensing income. PBI's revenue is generated through active Exploitation of pharmaceutical IP in competitive global markets.
V.G. Comparative DEMPE Assessment: PBI vs. PPC
The following summary matrix provides a high-level comparison of the DEMPE functions performed by PBI (Ireland) and PPC (United States) during the Examination Years. A more detailed product-specific DEMPE breakdown is provided in the DEMPE Functions Matrix workbook (see Appendix G).
Conclusion: The DEMPE functions are genuinely divided between PPC and PBI consistent with the CSA's territorial split and PBI's role as the non-Americas principal. PBI is not a passive entity relying on PPC to perform DEMPE functions on its behalf. PBI performs substantial and independent DEMPE functions from its operations in Ireland, using its own personnel, resources, and judgment. The division of DEMPE functions between PPC and PBI reflects a genuine allocation of responsibilities, risks, and assets that is consistent with the arm's-length standard and the economic substance of the parties' arrangement.
VI. Risk Analysis